RxDoctor Payments Data

Joshua Brandon, MD

Family Medicine · Louisville, KYNPI 1205458650

Payments from drug & device makers

$3,348in general payments, 2019–2025

Across 56 payments — averaging $59.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Novo Nordisk$845
  • Phathom Pharmaceuticals, Inc.$371
  • Lilly USA, LLC$340
  • AbbVie$302
  • Amgen$249
  • plus $134 from 2 others

What the payments were for

  • Food & beverage$3,348100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca17$1,106
Novo Nordisk9$845
Phathom Pharmaceuticals, Inc.3$371
Lilly USA, LLC10$340
AbbVie10$302
Amgen5$249
Bayer1$120
Pfizer1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,348 in reported general payments places this provider in the 75th percentile of 1,559 family medicine providers in Kentucky.

See all family medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$106,176
Medicare patients
234
Services billed
1,472

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide72$92,324
OzempicSemaglutide55$70,808
EliquisApixaban49$63,847
TrulicityDulaglutide24$27,184
Trelegy ElliptaFluticasone/Umeclidin/Vilanter34$26,918
JardianceEmpagliflozin23$20,163
Tresiba Flextouch U-100Insulin Degludec15$17,177
Spiriva RespimatTiotropium Bromide15$9,195
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog17$6,859
Lantus SolostarInsulin Glargine,hum.Rec.Anlog28$2,988
Albuterol Sulfate HfaAlbuterol Sulfate111$2,392
Atorvastatin Calcium329$2,266
Levothyroxine Sodium202$2,158
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen167$2,147
Ultra-Fine Mini Pen NeedlePen Needle, Diabetic16$1,626

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$340$119,50896 claims
Novo NordiskOzempic$845$70,80855 claims
PfizerEliquis$14$63,84749 claims
AbbVieSynthroid$302$1,28125 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,559 family medicine providers in Kentucky.

Other family medicine in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →